Compare Merck & Co., Inc. (MRK) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while GraniteShares 2x Long NVDA Daily ETF trades at $35.49. The key difference: Merck & Co., Inc. pays a 2.29% dividend while GraniteShares 2x Long NVDA Daily ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.
| MRK | NVDL | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $156.43 | $43.02 |
52-Week Low | $77.60 | $21.76 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.18, down 4.01% amid recent volatility. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. The ETF recently underwent two 1:3 stock splits in late June 2026, reflecting NVIDIA's continued market leadership in AI semiconductors.
The outlook remains positive given NVIDIA's dominant AI position and earnings beats, though leveraged ETF structure introduces volatility decay risks. Key opportunities include exposure to NVIDIA's growth trajectory, while risks center on market sentiment shifts and the ETF's daily reset mechanism affecting long-term returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
